In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...